Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 365

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

c-MET as a potential therapeutic target and biomarker in cancer

Open access
Sierra, J. Rafael, Tsao, Ming-Sound·2011·Therapeutic Advances in Medical Oncology

Abstract

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1758834011422557

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 145 references

Cited by

See all 365

Metadata

Authors
Sierra, J. R., & Tsao, M.-S.
Venue
Therapeutic Advances in Medical Oncology
Published
2011-11
Volume
3
Issue
1_suppl
Pages
S21-S35
ISSN
  • 1758-8340 (ISSN-L)
  • 1758-8359
OpenAlex
W2122895515
Cited by
365
References
145
FWCI
13.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: c-MET as a potential therapeutic target and biomarker in cancer. https://app.cochat.ai/papers/10.1177/1758834011422557
The paper
Sierra, J. R., & Tsao, M.-S. (2011). c-MET as a potential therapeutic target and biomarker in cancer. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834011422557

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.